Tecartus Suspension
Product Images NDC 71287-220

10 FDA label images from Kite Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tecartus (NDC 71287-220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kite Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (68 mL Bag Label)

Principal Display Panel (68 mL Bag Label)
Label for TECARTUS brexucabtagene autoleucel cellular therapy suspension for intravenous use. The label indicates a sterile bag containing up to 2 x 10^8 autologous anti-CD19 CAR T cells in approximately 68 mL suspension with 5% DMSO. It includes storage instructions at or below -120°C and warnings against use of leukodepleting filters and irradiation. Manufactured by Kite Pharma, Inc.*
FDA Label Image

Principal Display Panel (68 mL Cassette Label)

Principal Display Panel (68 mL Cassette Label)
Drug label text panel for brexucabtagene autoleucel (TECARTUS) cellular therapy suspension for intravenous use. It includes dosing as one sterile bag for infusion, storage instructions in a liquid nitrogen dry shipper, warnings against using a leukodepleting filter or irradiating, and additional manufacturing details by Kite Pharma, Inc. Contact and license information is also shown.*
FDA Label Image

Principal Display Panel (68 mL Bag Label)

Principal Display Panel (68 mL Bag Label)
Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension for intravenous use by Kite Pharma, Inc. The label includes patient verification instructions, lot number, patient IDs, expiration date placeholder, patient name placeholders, date of birth placeholder, barcode, and a QR code.*
FDA Label Image

Principal Display Panel (68 mL Cassette Label)

Principal Display Panel (68 mL Cassette Label)
Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension for intravenous use by Kite Pharma, Inc. It includes prominent patient identification verification instructions with a stop sign icon and fields for lot number, patient IDs, expiration date, patient name and DOB, and a barcode with DIN information.*
FDA Label Image

Principal Display Panel (68 mL LN2 Label)

Principal Display Panel (68 mL LN2 Label)
Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension by Kite Pharma, Inc., site FXX. The label includes placeholders for expiration date, cell order number, and lot number with associated barcodes. Storage instructions specify liquid nitrogen dry shipper and storage at or below -120°C. Manufacturer address at 2400 Broadway, Santa Monica, CA is also shown.*
FDA Label Image

Principal Display Panel (68 mL Bag Label)

Principal Display Panel (68 mL Bag Label)
Label for TECARTUS brexucabtagene autoleucel suspension for intravenous use. The label states it is for autologous use only, with one sterile bag for infusion containing approximately 68 mL suspension with anti-CD19 CAR T cells. Storage instructions specify liquid nitrogen dry shipper and temperatures at or below -120°C. Manufactured by Kite Pharma, Inc.*
FDA Label Image

Principal Display Panel (68 mL Cassette Label)

Principal Display Panel (68 mL Cassette Label)
Label for TECARTUS brexucabtagene autoleucel suspension for intravenous use by Kite Pharma, Inc. Contains up to 1 x 10^8 autologous anti-CD19 CAR T cells in approximately 68 mL suspension with 5% DMSO USP. Instructions include gentle mixing while thawing, storage in liquid nitrogen dry shipper at or below -120°C, and warnings against use of leukodepleting filters or irradiation. No preservatives included. Manufacturer and contact information listed.*
FDA Label Image

Principal Display Panel (68 mL Bag Label)

Principal Display Panel (68 mL Bag Label)
Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension. The label includes patient verification information such as Lot number, Kite Patient ID, Expiration Date, Patient name, Date of Birth, and Hospital Patient ID. It also shows a barcode and a QR code for identification purposes. Labeler is Kite Pharma, Inc.*
FDA Label Image

Principal Display Panel (68 mL Cassette Label)

Principal Display Panel (68 mL Cassette Label)
Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension by Kite Pharma, Inc. It includes a red stop sign instructing to confirm patient ID prior to infusion, and patient-specific details such as lot number, patient ID, expiration date, name, date of birth, hospital patient ID, and a barcode with DIN.*
FDA Label Image

Principal Display Panel (68 mL LN2 Label)

Principal Display Panel (68 mL LN2 Label)
Label for TECARTUS (brexucabtagene autoleucel) cellular therapy by Kite Pharma, Inc. It includes placeholders for expiration date, cell order number, and lot number with corresponding barcodes. Storage instructions specify shipping in liquid nitrogen dry shipper and storage at or below -120°C. Address details for Kite Pharma, Inc. in Santa Monica, CA, are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.